The strong revenue growth trajectory and FDA acceptance of the sBLA are positive catalysts, but persistent deep losses and a history of post-earnings stock declines suggest caution. Monitor for the PDUFA date in January 2027 and any updates on the planned sBLA submission for the BCG-naive NMIBC trial.
Price Chart
Executive Summary
ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth consecutive quarter of growth. The FDA accepted the sBLA for ANKTIVA in BCG-unresponsive NMIBC with a PDUFA date of Jan 6, 2027. While revenue growth is strong, the company remains deeply unprofitable on both a GAAP and adjusted basis, with a GAAP net loss of $230.4M and an adjusted net loss of $81.0M for the quarter, and the stock has historically declined significantly following prior reports, warranting a neutral stance despite the positive operational trends.
Key Financial Metrics
Key Facts
- Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially from Q1 2026.
- First-half 2026 net product revenue of $94.8M, up 121% YoY.
- FDA accepted sBLA for ANKTIVA in BCG-unresponsive NMIBC with papillary-only disease; PDUFA date Jan 6, 2027.
- GAAP net loss attributable to common stockholders was $230.4M in Q2 2026 vs $92.6M in Q2 2025.
- Adjusted net loss (non-GAAP) was $81.0M in Q2 2026 vs $89.9M in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $357.4M as of June 30, 2026.
- Entered exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG.
- Eighth consecutive quarter of sequential net product revenue growth since ANKTIVA's commercial launch.
Financial Impact
Q2 2026 net product revenue of $50.7M, up 92% YoY; GAAP net loss of $230.4M; adjusted net loss of $81.0M
Risk Factors
- Persistent GAAP and adjusted net losses despite revenue growth.
- High operating expenses (R&D and SG&A) continue to outpace revenue growth.
- Significant non-cash fair value losses on convertible note and warrant liabilities due to stock price increases.
- Historical stock performance shows large declines following prior earnings reports.
- Dependence on successful regulatory approvals and commercial expansion of ANKTIVA.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326110-26-000077 |
| Document: ibrx-20260804.htm | 0001326110-26-000077 |
| Document: 0001326110-26-000077-index-headers.html | 0001326110-26-000077 |
| Document: 0001326110-26-000077-index.html | 0001326110-26-000077 |
| Document: 0001326110-26-000077.txt | 0001326110-26-000077 |
| 8-K Data (Synthetic) | 0001326110-26-000077 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $6.95 $7.87 | ▲ +13.24% | ▲ +14.48% | $10.28 (+47.99%) |
Jul 6, 2026 12w ago | Insider Cluster | $8.91 $7.17 | ▼ −19.53% | ▼ −18.96% | $10.28 (+15.43%) |
Jul 1, 2026 13w ago | Insider Cluster | $9.20 $6.83 | ▼ −25.76% | ▼ −23.58% | $10.28 (+11.79%) |
May 18, 2026 19w ago | 8-K | $7.76 $6.99 | ▼ −9.92% | ▼ −10.91% | $10.28 (+32.54%) |
Apr 9, 2026 25w ago | 8-K | $7.48 $8.38 | ▲ +12.03% | ▲ +4.46% | $10.28 (+37.50%) |
Apr 6, 2026 25w ago | 8-K | $7.08 $7.43 | ▲ +4.94% | ▼ −4.04% | $10.28 (+45.27%) |
Feb 28, 2026 30w ago | Institutional Cluster | $10.44 $6.66 | ▼ −36.21% | ▼ −28.27% | $10.28 (−1.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access